AU2016342387B2 - Stem cell therapy based on adipose-derived stem cells - Google Patents

Stem cell therapy based on adipose-derived stem cells Download PDF

Info

Publication number
AU2016342387B2
AU2016342387B2 AU2016342387A AU2016342387A AU2016342387B2 AU 2016342387 B2 AU2016342387 B2 AU 2016342387B2 AU 2016342387 A AU2016342387 A AU 2016342387A AU 2016342387 A AU2016342387 A AU 2016342387A AU 2016342387 B2 AU2016342387 B2 AU 2016342387B2
Authority
AU
Australia
Prior art keywords
cells
composition
ascs
asc
express
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016342387A
Other languages
English (en)
Other versions
AU2016342387A1 (en
Inventor
Annette EKBLOND
Mandana Haack-Sørensen
Jens Kastrup
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigshospitalet
Original Assignee
Rigshospitalet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigshospitalet filed Critical Rigshospitalet
Publication of AU2016342387A1 publication Critical patent/AU2016342387A1/en
Application granted granted Critical
Publication of AU2016342387B2 publication Critical patent/AU2016342387B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0662—Stem cells
    • C12N5/0667—Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/34—Sugars
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/38—Vitamins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides or bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/44—Thiols, e.g. mercaptoethanol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/60—Buffer, e.g. pH regulation, osmotic pressure
    • C12N2500/62—DMSO
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/80—Undefined extracts from animals
    • C12N2500/84—Undefined extracts from animals from mammals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
AU2016342387A 2015-10-23 2016-10-21 Stem cell therapy based on adipose-derived stem cells Active AU2016342387B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15191213 2015-10-23
EP15191213.6 2015-10-23
PCT/EP2016/075407 WO2017068140A1 (en) 2015-10-23 2016-10-21 Stem cell therapy based on adipose-derived stem cells

Publications (2)

Publication Number Publication Date
AU2016342387A1 AU2016342387A1 (en) 2018-04-26
AU2016342387B2 true AU2016342387B2 (en) 2021-12-09

Family

ID=54360137

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2016342387A Active AU2016342387B2 (en) 2015-10-23 2016-10-21 Stem cell therapy based on adipose-derived stem cells

Country Status (13)

Country Link
US (2) US12433916B2 (https=)
EP (1) EP3365432B1 (https=)
JP (2) JP2018531269A (https=)
KR (1) KR20180063334A (https=)
CN (1) CN108135942A (https=)
AU (1) AU2016342387B2 (https=)
CA (1) CA3000912C (https=)
DK (1) DK3365432T3 (https=)
ES (1) ES2807897T3 (https=)
PL (1) PL3365432T3 (https=)
PT (1) PT3365432T (https=)
SI (1) SI3365432T1 (https=)
WO (1) WO2017068140A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3112505C (en) 2018-09-20 2023-06-20 Citospin, S.L. Method for obtaining an enriched population of functional mesenchymal stem cells, cells obtained thereof and compositions comprising the same
EP3923959A1 (en) 2019-02-15 2021-12-22 Rigshospitalet Stem cell therapy for patients with salivary gland dysfunction
EP3923960A1 (en) 2019-02-15 2021-12-22 Rigshospitalet, Copenhagen University Hospital Stem cell therapy for lacrimal gland dysfunction
CN111269888B (zh) * 2020-03-24 2022-04-08 山东兴瑞生物科技有限公司 一种adipsin基因修饰的脂肪干细胞、制备方法及其应用
EP3909593A1 (en) 2020-05-15 2021-11-17 Rigshospitalet Stem cells for treating skin lesions
TWI825446B (zh) * 2020-08-14 2023-12-11 中國醫藥大學 醫藥組合物治療組織缺血狀況之用途
US12426594B2 (en) 2020-09-24 2025-09-30 Everest Medical Innovation GmbH Cryoprotective compositions and methods for protection of a surgical site during cryosurgery
US12453805B2 (en) 2020-09-24 2025-10-28 Everest Medical Innovation GmbH Cryoprotective compositions, surgical kits, and methods for protection of a surgical site during cryosurgery
CO2020012570A1 (es) 2020-10-08 2022-04-08 Inst Distrital De Ciencia Biotecnologia E Innovacion En Salud Idcbis Método de estimulación de células mesenquimales para inducir expresión de factores inmunomoduladores

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492103B1 (en) * 2000-01-31 2002-12-10 Organ Recovery Systems, Inc. System for organ and tissue preservation and hypothermic blood substitution
US20090304654A1 (en) * 2008-04-30 2009-12-10 Regents Of The University Of California Methods for isolating adipose-derived stem cells and therapeutic use thereof
WO2014074859A1 (en) * 2012-11-08 2014-05-15 Ingeneron Inc. Media for culturing, preserving, and administering regenerative cells
WO2014203267A2 (en) * 2013-06-17 2014-12-24 Kasiak Research Pvt. Ltd. Method for isolation, purification and industrial scale expansion of human adipose tissue derived mesenchymal stem cells

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6045990A (en) 1998-07-09 2000-04-04 Baust; John M. Inclusion of apoptotic regulators in solutions for cell storage at low temperature
US20060045872A1 (en) 2004-08-25 2006-03-02 Universidad Autonoma De Madrid Ciudad Universitaria de Cantoblanco Use of adipose tissue-derived stromal stem cells in treating fistula
ES2313805B1 (es) 2004-10-04 2009-12-23 Cellerix, S.L. Identificacion y aislamiento de celulas multipotentes de tejido mesenquimal no osteocondral.
TW200726474A (en) 2005-07-15 2007-07-16 Cognate Therapeutics Inc The immunophenotype and immunogenicity of human adipose derived cells
US9598673B2 (en) 2006-05-19 2017-03-21 Creative Medical Health Treatment of disc degenerative disease
CN102124098B (zh) * 2008-06-27 2014-03-12 博傲沃德株式会社 细胞及组织的冷冻保存用组合物
GB0822246D0 (en) 2008-12-05 2009-01-14 Reneuron Ltd Composition
KR101344719B1 (ko) * 2011-07-19 2013-12-26 한국과학기술연구원 응력을 가하여 줄기세포를 평활근세포로 분화시키는 방법 및 평활근세포를 함유하는 조직공학용 복합체
CN103074298B (zh) * 2013-01-04 2015-10-21 冯文峰 一种人脂肪间充质干细胞库及其构建方法
CN104357382A (zh) 2014-10-08 2015-02-18 黑龙江天晴干细胞有限公司 人脂肪干细胞的获取方法及多级同种异体脂肪干细胞库的构建方法
CN108348555B (zh) * 2015-09-08 2022-07-08 赛尔爱迪尔私人有限公司 细胞扩增方法和治疗组合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492103B1 (en) * 2000-01-31 2002-12-10 Organ Recovery Systems, Inc. System for organ and tissue preservation and hypothermic blood substitution
US20090304654A1 (en) * 2008-04-30 2009-12-10 Regents Of The University Of California Methods for isolating adipose-derived stem cells and therapeutic use thereof
WO2014074859A1 (en) * 2012-11-08 2014-05-15 Ingeneron Inc. Media for culturing, preserving, and administering regenerative cells
WO2014203267A2 (en) * 2013-06-17 2014-12-24 Kasiak Research Pvt. Ltd. Method for isolation, purification and industrial scale expansion of human adipose tissue derived mesenchymal stem cells

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Technical Support, "CRYOSTOR(TM) QUICK REFERENCE CRYOPRESERVATION PROTOCOL", (2012-06-17), URL: http://web.archive.org/web/20120619212341/http://biolifesolutions.com/biopreservation-media/Protocol_CryoStor.pdf, (2016-11-29) *
WANG, L., et al., "Adipose-derived stem cells are an effective cell candidate for treatment of heart failure: an MR imaging study of rat hearts", Am J Physiol Heart Circ Physiol. 2009, Vol. 297, No. 3, pages H1020-H1031 *

Also Published As

Publication number Publication date
US20260007702A1 (en) 2026-01-08
JP2022084665A (ja) 2022-06-07
DK3365432T3 (en) 2020-07-27
CA3000912A1 (en) 2017-04-27
CN108135942A (zh) 2018-06-08
AU2016342387A1 (en) 2018-04-26
JP2018531269A (ja) 2018-10-25
PT3365432T (pt) 2020-07-27
ES2807897T3 (es) 2021-02-24
WO2017068140A1 (en) 2017-04-27
PL3365432T3 (pl) 2020-09-21
KR20180063334A (ko) 2018-06-11
EP3365432B1 (en) 2020-05-06
SI3365432T1 (sl) 2020-08-31
US12433916B2 (en) 2025-10-07
EP3365432A1 (en) 2018-08-29
US20180325957A1 (en) 2018-11-15
CA3000912C (en) 2024-01-09

Similar Documents

Publication Publication Date Title
US20260007702A1 (en) Stem cell therapy based on adipose-derived stem cells
JP2018531269A6 (ja) 脂肪由来幹細胞に基づく幹細胞治療
Bieback et al. Clinical protocols for the isolation and expansion of mesenchymal stromal cells
EP2086556B1 (en) Mixed cell populations for tissue repair and separation technique for cell processing
US8481253B2 (en) Cryopreservation of adipose tissue for the isolation of mesenchymal stem cells
KR102505009B1 (ko) 치료 용도를 위한 푸코실화된 세포의 제조 및 동결보존
JP5341059B2 (ja) 幹細胞懸濁液
Badowski et al. Mixed effects of long-term frozen storage on cord tissue stem cells
CA2649874C (en) Immune privileged and modulatory progenitor cells
EP3984596A1 (en) Cell population including mesenchymal cells, pharmaceutical composition including same, and method for producing same
CA2836102A1 (en) Mesenchymal stromal cell populations and methods of making same
JP5753874B2 (ja) 細胞生存率低下抑制剤
HK1259517A1 (en) Stem cell therapy based on adipose-derived stem cells
HK1259517B (en) Stem cell therapy based on adipose-derived stem cells
Sari et al. A Proliferation and surface marker characterization of adipose stem cells after culture in various processed outdated platelet lysate containing media
JP7833271B2 (ja) 接着性幹細胞製剤の製造方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)